<DOC>
	<DOCNO>NCT01327963</DOCNO>
	<brief_summary>The purpose open-label , postmarket study evaluate safety efficacy transoral incisionless fundoplication ( TIF ) perform EsophyX broad range gastroesophageal reflux disease ( GERD ) patient treat high volume center across United States .</brief_summary>
	<brief_title>Retrospective TIF Study Treatment Gastroesophageal Reflux Disease ( GERD ) . The RetroTIF Study</brief_title>
	<detailed_description>This open-label , postmarket study evaluate safety efficacy transoral incisionless fundoplication ( TIF ) perform EsophyX broad range gastroesophageal reflux disease ( GERD ) patient treat high volume center across United States , clinical routine practice , standard care .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Age 1885 year Have undergone TIF procedure within past 2 year Availability followup visit 12 24 month Willingly cognitively sign inform consent Procedure complete perform follow nonstandardized TIF protocol Subjects suffer GI condition dyspepsia , celiac disease , IBS Crohn 's disease Pregnancy Enrollment another device drug study may confound result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gastroesophageal reflux disease</keyword>
	<keyword>GERD</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Reflux</keyword>
	<keyword>Regurgitation</keyword>
	<keyword>Hoarseness</keyword>
	<keyword>Cough</keyword>
</DOC>